Cargando…
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit the use of a broad therapeutic arsenal in patients with HCC. Although main HCC oncogenic dr...
Autores principales: | Hilmi, Marc, Neuzillet, Cindy, Calderaro, Julien, Lafdil, Fouad, Pawlotsky, Jean-Michel, Rousseau, Benoit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884868/ https://www.ncbi.nlm.nih.gov/pubmed/31783782 http://dx.doi.org/10.1186/s40425-019-0824-5 |
Ejemplares similares
-
Interleukins‐17 and 27 promote liver regeneration by sequentially inducing progenitor cell expansion and differentiation
por: Guillot, Adrien, et al.
Publicado: (2018) -
Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through miR-122 downregulation with increased risk of primary liver cancer initiation
por: Gasmi, Imène, et al.
Publicado: (2022) -
Immune Therapy for Liver Cancers
por: Hilmi, Marc, et al.
Publicado: (2019) -
Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions
por: Perisetti, Abhilash, et al.
Publicado: (2022) -
Surveillance of hepatocellular carcinoma in cirrhotic patients: Current knowledge and future directions
por: Demirtas, Coskun Ozer, et al.
Publicado: (2020)